Barclays
MJN

Barclays’s Mead Johnson Nutrition Company MJN Stock Holding History

Barclays’s Portfolio MJN Stock Details MJN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-248,400
Closed -$22.1M – 7202
2017
Q1 		$22.1M Buy
248,400
+215,400
+653% +$17.7M 0.02% 528
2016
Q4 		$2.33M Sell
33,000
-26,300
-44% -$1.96M ﹤0.01% 1992
2016
Q3 		$4.69M Buy
59,300
+500
+0.9% +$42.6K 0.01% 1356
2016
Q2 		$5.34M Sell
58,800
-39,800
-40% -$3.37M 0.01% 1261
2016
Q1 		$8.28M Buy
98,600
+63,500
+181% +$4.72M 0.01% 862
2015
Q4 		$2.74M Buy
35,100
+32,000
+1,032% +$2.52M ﹤0.01% 1776
2015
Q3 		$217K Sell
3,100
-6,000
-66% -$494K ﹤0.01% 4087
2015
Q2 		$819K Sell
9,100
-600
-6% -$57.9K ﹤0.01% 3062
2015
Q1 		$970K Buy
9,700
+4,300
+80% +$434K ﹤0.01% 3008
2014
Q4 		$540K Sell
5,400
-55,300
-91% -$5.51M ﹤0.01% 3799
2014
Q3 		$5.83M Sell
60,700
-35,700
-37% -$3.38M 0.01% 1634
2014
Q2 		$8.97M Sell
96,400
-2,800
-3% -$245K 0.01% 1240
2014
Q1 		$8.23M Buy
99,200
+70,100
+241% +$5.68M 0.01% 1294
2013
Q4 		$2.42M Sell
29,100
-7,800
-21% -$635K ﹤0.01% 2477
2013
Q3 		$2.73M Sell
36,900
-15,900
-30% -$1.19M ﹤0.01% 2238
2013
Q2 		$4.18M Buy
+52,800
New +$4.23M 0.01% 1771

Other funds holding MJN

PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
FNBOO
First National Bank of Omaha Omaha, Nebraska $3.24B AUM 18.68% 1-Year Est. Return
LFAS
Level Four Advisory Services Dallas, Texas $3.05B AUM 23.96% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $4.48B AUM 19.29% 1-Year Est. Return
WEC
Winslow Evans & Crocker Boston, Massachusetts $528M AUM 30.99% 1-Year Est. Return

Barclays's MJN Position: Q2 2017 in Review

Barclays sold out of Mead Johnson Nutrition Company (MJN) in Q2 2017, closing a stake of 881,402 shares — an estimated $78.5M sold.

Barclays first reported a position in MJN in Q2 2013 and held it in 16 quarters. The position peaked at $78.5M in Q1 2017. 7 funds tracked by Wall St. Rank hold MJN as of Q2 2017.

  • Barclays reported no remaining Mead Johnson Nutrition Company position as of Q2 2017 after selling out during the quarter.
  • Barclays sold 881,402 Mead Johnson Nutrition Company shares in Q2 2017, an estimated $78.5M.
  • Barclays first reported a position in Mead Johnson Nutrition Company in Q2 2013 and held it in 16 quarters.
  • Barclays's Mead Johnson Nutrition Company position peaked at $78.5M in Q1 2017.
  • 7 funds tracked by Wall St. Rank held Mead Johnson Nutrition Company as of Q2 2017.

Based on Barclays's 13F filing for Q2 2017, filed 14 Aug 2017.